North America Melanoma Therapeutics Market

North America Melanoma Therapeutics Market Size (2023 to 2028)

The melanoma therapeutics market in North America was worth USD 1.41 billion in 2023 and is estimated to be growing at a CAGR of 15.95%, to reach USD 2.96 billion by 2028. 

The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.

Melanoma denotes the type of skin cancer that forms from the pigment-consisting cells in the skin. The elevated demand for innovative early-stage and advanced melanoma treatments, along with a thriving patient base, has generated an imminent need for improved therapies in the melanoma market. Even though many treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive on the market.

The market for melanoma therapeutics in North America is primarily driven by factors such as an increase in melanoma cases, a high acceptance rate of therapeutics among the patients, and government efforts to promote improved melanoma care. Also, with the growing patient base and strong demand for novel early-stage and advanced melanoma medicines, the melanoma industry is in desperate need of better treatments. As a result, several immunotherapies and combination therapies are projected to enter the market, even though there are various therapeutic choices accessible. Because of their higher survival benefits and few side effects, these innovative medicines are predicted to be widely adopted. In addition, an untapped patient pool will contribute to a significant uptake of innovative drugs in the forecast period.

On the other hand, the increased account of research and development operations from private and public organizations for creating affordable and effective treatments is expected to improve the melanoma therapeutics market’s growth opportunities. In addition, the patent expiration of prominent medications is expected to provide numerous chances for the North American melanoma therapeutics market to grow over the forecast period.

The North American melanoma therapeutics market’s growth rate is predicted to be hampered by the issues such as a lack of awareness in some emerging nations and the high cost of treatment. Furthermore, the melanoma therapeutics market is being held back by the economic downturn and regulatory problems.

This research report on the North America Melanoma Therapeutics Market is segmented and sub-segmented into the following categories:

By Cancer Stage:

• Stage 0
• Stage I
• Stage II
• Stage III
• Stage IV

By Cancer Type:

• Nodular Melanoma
• Acral Lentiginous Melanoma
• Superficial Spreading Melanoma
• Lentigno Maligna Melanoma
• Amelanotic Melanoma
• Others

By Diagnosis:

• Ultrasound
• Blood Tests
• Dermatoscopy
• Sentinel Lymph Node Biopsy
• X-rays
• CT Scan

By Treatment:

• Early Melanoma
• Advanced Melanoma-Biological Therapy
• Targeted Therapy
• Surgery
• Chemotherapy
• Radiotherapy
• Immune Therapy

By Country: 

• United States
• Canada
• Rest of North America

Geographically, the North American regional market held the largest share of the global Melanoma therapeutics market in 2020. The market is projected to witness a prominent share during the forecast period. The factors such as the rising number of melanoma patients and technical improvements in this region are driving the market growth. Furthermore, the increasing incidence of melanoma and other skin malignancies is considerably propelling this region’s market expansion. Melanoma infected roughly 88,000 persons in the United States in 2017, according to the CDC. As a result, this measurement will aid in the management of melanoma cases in the coming years.

Furthermore, the United States largely contributes due to favorable payment rules for treating diseases and the government’s development of unmet patient requirements. The Surgeon General Call to Action to Prevent Skin Cancer was announced in July 2014 by the Office of the Surgeon General, making skin cancer prevention a top priority for the country. The Call of Action outlined effective skin cancer prevention techniques and urged all community sectors to confront skin cancer as a significant public health issue. Since the Call of Action was issued, a growing community of national, state and local partners has worked hard to help prevent skin cancer in the United States.

The U.S. melanoma therapeutics market dominated the North American market with a significant share in 2020, and it is likely to continue its growth throughout the forecast period. In the United States, over 98% of melanoma are localized. In the United States, skin cancer is the most frequent cancer. Biologic therapy, immune therapy, radiation therapy, chemotherapy, and surgery are all options for melanoma treatment. California has the largest melanoma treatment market in the United States, followed by Florida. Further, the market is expected to be driven by technological advancements in melanoma therapy and diagnostics in the United States.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America melanoma therapeutics market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.